Respiratory Solutions

• Value: £19M

Products within this lot are oxygen therapy products used to administer oxygen. Products will include but are not limited to: oxygen facemasks, nasal cannula, venturi valves, tracheostomy facemasks, oxygen tubing, flowmeters, oxygen catheters and oxygen therapy adaptors/connectors. Additional information: It is anticipated that in the first 24 months of the Framework Agreement, the value of purchases for this Lot will be circa £9,431,491 and for the full 48-month term (if extended), the anticipated value is circa £19,244,019. These values are approximate only and are based on the most recent historical usage information, with a forecasted level of growth from year 1 to 4.

• Value: £12M

Products within this Lot are aerosol therapy products used to administer medicines via the breathing of a patient. Products will include but are not limited to: nebuliser products, nebuliser filter, compressor nebulisation, spacer for metered doe inhaler, valved tee adaptor, and aerosol facemasks. Additional information: It is anticipated that in the first 24 months of the Framework Agreement, the value of purchases for this Lot will be circa £5,830,096 and for the full 48-month term (if extended), the anticipated value is circa £11,895,727. These values are approximate only and are based on the most recent historical usage information, with a forecasted level of growth from year 1 to 4.

• Value: £11M

Products within this Lot relate to respiratory therapy for patients. These products can support the removal of secretions from the lungs and aim to reduce the occurrence of respiratory infections and the ensuing requirement for antibiotics or hospitalisation. Additional information: It is anticipated that in the first 24 months of the Framework Agreement, the value of purchases for this Lot will be circa £5,585,775 and for the full 48-month term (if extended), the anticipated value is circa £11,397,215. These values are approximate only and are based on the most recent historical usage information, with a forecasted level of growth from year 1 to 4.

• Value: £7M

This Lot is for products that support anaesthesia and resuscitation medical gas treatment, monitoring and diagnosis. Resuscitation products also relate to teaching and administering resuscitation to adults and children. Additional information: It is anticipated that in the first 24 months of the Framework Agreement, the value of purchases for this Lot will be circa £3,565,775 and for the full 48-month term (if extended), the anticipated value is circa £7,275,607. These values are approximate only and are based on the most recent historical usage information, with a forecasted level of growth from year 1 to 4.

• Value: £10M

Products within this lot are respiratory diagnostic tools. Products will include but are not limited to: gas monitoring lines, spirometers, bacterial viral filter, peak flow meter, carbon dioxide monitor and baby respiration monitor. Additional information: It is anticipated that in the first 24 months of the Framework Agreement, the value of purchases for this Lot will be circa £4,760,492 and for the full 48-month term (if extended), the anticipated value is circa £9,713,307. These values are approximate only and are based on the most recent historical usage information, with a forecasted level of growth from year 1 to 4.

• Value: £1M

Products within this Lot are for cold humidification and nebulisation including sterile water. Products within this lot include but are not limited to: humidifiers, humidifier kit, humidification column, humidifier adaptor and sterile water for humidification. Additional information: It is anticipated that in the first 24 months of the Framework Agreement, the value of purchases for this Lot will be circa £604,420 and for the full 48-month term (if extended), the anticipated value is circa £1,233,259. These values are approximate only and are based on the most recent historical usage information, with a forecasted level of growth from year 1 to 4.